Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02703714 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and GM-CSF in Biliary Cancer
A Phase 2 study of Biliary Cancer, sponsored by Robin Kate Kelley.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT02703714: Completed Phase 2 study of Biliary Cancer, sponsored by Robin Kate Kelley.
NCT02703714 is a Phase 2 study of Biliary Cancer that has completed, run by Robin Kate Kelley. The registered enrollment target is 42 participants, below the 182-participant average among 9 other Biliary Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02703714, a Phase 2 study of Biliary Cancer, has completed, sponsored by Robin Kate Kelley.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at University of California, San Francisco (UCSF). This phase II study will examine the efficacy and safety of the novel combination of pembrolizumab plus induction GM-CSF in advanced biliary cancer patients with the hypotheses that the combination may increase proportion of patients with overall response compared to contemporary historical controls, with acceptable safety.
Primary Outcome
Proportion of subjects with measurable disease at study entry who obtained either a complete response (CR) or partial response (PR) (confirmed + unconfirmed) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at any time during the course of treatment.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Sargramostim
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-05-06 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 2 |
What the finished NCT02703714 record still lists
NCT02703714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 182-participant average among 9 other Biliary Cancer trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Biliary Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02703714 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02703714 about?
NCT02703714 is a clinical study titled "Pembrolizumab and GM-CSF in Biliary Cancer". This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at University of California, San Francisco (UCSF). This phase II study will examine the efficacy and safety of the nove...
What is the current status of trial NCT02703714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2016-05-06. Estimated completion is 2020-12-31.
What conditions does trial NCT02703714 study?
This clinical trial studies the following conditions: Biliary Cancer.
What interventions are being tested in trial NCT02703714?
The interventions under investigation include: Pembrolizumab (DRUG), Sargramostim (DRUG).
Who is sponsoring clinical trial NCT02703714?
This trial is sponsored by Robin Kate Kelley, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02703714 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02703714's enrollment target sits among peer trials
42 7th of 9 higher than 3 of 9 other Biliary Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Biliary Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
COMPLETED · Phase 2
-
A Study of Patients Receiving High-Dose Rate Brachytherapy
COMPLETED · Phase 2
-
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
RECRUITING
-
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
RECRUITING · NA
-
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
RECRUITING · Phase 1
-
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI